Drugmakers need more guidance from the Centers for Medicare & Medicaid Services (CMS) on how to calculate the best price for drugs sold on Medicare Part B, a key federal watchdog said. The review, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results